<p>Aytu BioPharma 最近的财报电话会议充满了乐观和战略重点。公司对即将推出的 ExuA（治疗重度抑郁症的新型疗法）表示了极大的热情，并庆祝其连续第三年实现正向调整后 EBITDA。然而，会议也承认了一些挑战，例如毛利率下降和 ADHD 产品组合中潜在的竞争，这可能会在未来构成障碍。</p>
<h2>ExuA 推出计划</h2>
<p>Aytu BioPharma 正在为 ExuA 的推出做准备，这是一种突破性的重度抑郁症（MDD）治疗药物。这种首创药物预计将显著改变公司的市场地位。ExuA 作为 5-HT1A 受体激动剂的独特机制旨在满足 MDD 市场中未被满足的需求，通过减少与现有治疗相关的常见副作用，如性功能障碍和体重增加。</p>
<h2>正向调整后 EBITDA</h2>
<p>公司报告了连续第三年的正向调整后 EBITDA，达到 920 万美元（2025 财年）。这一成就突显了 Aytu BioPharma 的财务稳定性和有效的成本管理策略，增强了投资者对公司财务健康的信心。</p>
<h2>儿科产品组合增长</h2>
<p>Aytu BioPharma 的儿科产品组合表现出增长，净收入从 730 万美元增加到 880 万美元。这一增长反映了公司复苏增长计划的成功，突显了其扩展和利用儿科产品的能力。</p>
<h2>成功融资</h2>
<p>公司完成了一次成功的市场公开募股，筹集了 1660 万美元的总额和近 1500 万美元的净额。这轮融资由专注于医疗保健的机构投资者主导，为 Aytu BioPharma 提供了支持其战略举措和未来增长所需的资本。</p>
<h2>毛利率下降</h2>
<p>Aytu BioPharma 面临毛利率下降，从 75% 降至 69%。这一下降归因于 ADHD 库存销售成本的增加，主要是由于关闭制造设施带来的间接成本。公司专注于通过改善产品包装和成本结构来优化毛利率。</p>
<h2>ADHD 产品组合稳定性担忧</h2>
<p>ADHD 产品组合的净收入保持相对平稳，为 5760 万美元，较 5780 万美元略有下降，引发了对潜在仿制药竞争的担忧。公司意识到这些挑战，可能会专注于维持其市场地位的策略。</p>
<h2>减值费用影响</h2>
<p>在儿科产品组合上记录了 830 万美元的减值费用。这是由于战略重心转向 ExuA 和 ADHD 产品组合，表明资源的重新配置以利用更有前景的机会。</p>
<h2>前瞻性指导</h2>
<p>Aytu BioPharma 提供了 2025 财年的前瞻性指导，报告净收入为 6640 万美元，并强调 ExuA 即将推出的影响。公司计划利用其 Aytu RxConnect 平台实现高效的市场渗透，并准备在 2025 年底之前推出 ExuA。此外，Aytu 计划在 2026 财年投资约 1000 万美元用于 ExuA 的推出，并预计在随后的几个季度显著提升商业运营。</p>
<p>总之，Aytu BioPharma 的财报电话会议传达了积极的前景，受到 ExuA 预期推出和持续财务表现的推动。尽管承认了毛利率下降和 ADHD 市场潜在竞争等挑战，但公司的战略举措和财务成就为未来的增长提供了坚实的基础。</p>

AYTU

<p>Aytu BioPharma 的财报电话会议强调了对 ExuA 这一新型重度抑郁症治疗药物上市的乐观情绪，并报告了 2025 财年的调整后息税折旧摊销前利润（EBITDA）为 920 万美元。公司面临挑战，包括毛利率从 75% 下降至 69%，以及由于潜在竞争对其注意力缺陷多动障碍（ADHD）产品组合的担忧。Aytu 的儿科产品组合有所增长，公司通过公开发行筹集了 1660 万美元。展望未来，Aytu 预计 2025 财年的净收入为 6640 万美元，并计划在 ExuA 的上市上投资 1000 万美元</p>

<p>Aytu BioPharma’s recent earnings call was marked by a sense of optimism and strategic focus. The company expressed significant enthusiasm about the upcoming launch of ExuA, a novel treatment for major depressive disorder, and celebrated its third consecutive year of positive adjusted EBITDA. However, the call also acknowledged challenges such as a decline in gross margin and potential competition in the ADHD portfolio, which could pose hurdles moving forward.</p>
<div class="lb-trans"><p>Aytu BioPharma 最近的财报电话会议充满了乐观和战略重点。公司对即将推出的 ExuA（治疗重度抑郁症的新型疗法）表示了极大的热情，并庆祝其连续第三年实现正向调整后 EBITDA。然而，会议也承认了一些挑战，例如毛利率下降和 ADHD 产品组合中潜在的竞争，这可能会在未来构成障碍。</p>
</div><h2>ExuA Launch Plans</h2>
<div class="lb-trans"><h2>ExuA 推出计划</h2>
</div><p>Aytu BioPharma is gearing up for the launch of ExuA, a groundbreaking treatment for major depressive disorder (MDD). This first-in-class medication is expected to significantly transform the company’s market presence. ExuA’s unique mechanism as a 5-HT1A receptor agonist aims to address unmet needs in the MDD market by reducing common side effects associated with existing treatments, such as sexual dysfunction and weight gain.</p>
<div class="lb-trans"><p>Aytu BioPharma 正在为 ExuA 的推出做准备，这是一种突破性的重度抑郁症（MDD）治疗药物。这种首创药物预计将显著改变公司的市场地位。ExuA 作为 5-HT1A 受体激动剂的独特机制旨在满足 MDD 市场中未被满足的需求，通过减少与现有治疗相关的常见副作用，如性功能障碍和体重增加。</p>
</div><h2>Positive Adjusted EBITDA</h2>
<div class="lb-trans"><h2>正向调整后 EBITDA</h2>
</div><p>The company reported a positive adjusted EBITDA for the third consecutive year, reaching $9.2 million for fiscal 2025. This achievement underscores Aytu BioPharma’s financial stability and effective cost management strategies, reinforcing investor confidence in the company’s financial health.</p>
<div class="lb-trans"><p>公司报告了连续第三年的正向调整后 EBITDA，达到 920 万美元（2025 财年）。这一成就突显了 Aytu BioPharma 的财务稳定性和有效的成本管理策略，增强了投资者对公司财务健康的信心。</p>
</div><h2>Pediatric Portfolio Growth</h2>
<div class="lb-trans"><h2>儿科产品组合增长</h2>
</div><p>Aytu BioPharma’s pediatric portfolio demonstrated growth, with net revenue increasing from $7.3 million to $8.8 million. This growth reflects the success of the company’s return to growth plan, highlighting its ability to expand and capitalize on its pediatric offerings.</p>
<div class="lb-trans"><p>Aytu BioPharma 的儿科产品组合表现出增长，净收入从 730 万美元增加到 880 万美元。这一增长反映了公司复苏增长计划的成功，突显了其扩展和利用儿科产品的能力。</p>
</div><h2>Successful Financing</h2>
<div class="lb-trans"><h2>成功融资</h2>
</div><p>The company completed a successful at-the-market public offering, raising $16.6 million gross and just under $15 million net. This financing round was led by healthcare-focused institutional investors, providing Aytu BioPharma with the capital needed to support its strategic initiatives and future growth.</p>
<div class="lb-trans"><p>公司完成了一次成功的市场公开募股，筹集了 1660 万美元的总额和近 1500 万美元的净额。这轮融资由专注于医疗保健的机构投资者主导，为 Aytu BioPharma 提供了支持其战略举措和未来增长所需的资本。</p>
</div><h2>Decline in Gross Margin</h2>
<div class="lb-trans"><h2>毛利率下降</h2>
</div><p>Aytu BioPharma faced a decline in gross margin, which decreased from 75% to 69%. This drop was attributed to increased cost of sales in the ADHD inventory, primarily due to overhead costs from a closed manufacturing facility. The company is focused on optimizing gross margins through improved product packaging and cost structures.</p>
<div class="lb-trans"><p>Aytu BioPharma 面临毛利率下降，从 75% 降至 69%。这一下降归因于 ADHD 库存销售成本的增加，主要是由于关闭制造设施带来的间接成本。公司专注于通过改善产品包装和成本结构来优化毛利率。</p>
</div><h2>ADHD Portfolio Stability Concerns</h2>
<div class="lb-trans"><h2>ADHD 产品组合稳定性担忧</h2>
</div><p>The ADHD portfolio’s net revenue remained relatively flat at $57.6 million compared to $57.8 million, raising concerns about potential generic competition. The company is aware of these challenges and is likely to focus on strategies to maintain its market position.</p>
<div class="lb-trans"><p>ADHD 产品组合的净收入保持相对平稳，为 5760 万美元，较 5780 万美元略有下降，引发了对潜在仿制药竞争的担忧。公司意识到这些挑战，可能会专注于维持其市场地位的策略。</p>
</div><h2>Impairment Expense Impact</h2>
<div class="lb-trans"><h2>减值费用影响</h2>
</div><p>An $8.3 million impairment expense was recorded on the pediatric portfolio. This was due to a strategic shift in focus towards ExuA and the ADHD portfolio, indicating a realignment of resources to capitalize on more promising opportunities.</p>
<div class="lb-trans"><p>在儿科产品组合上记录了 830 万美元的减值费用。这是由于战略重心转向 ExuA 和 ADHD 产品组合，表明资源的重新配置以利用更有前景的机会。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Aytu BioPharma provided forward-looking guidance for fiscal 2025, reporting net revenue of $66.4 million and emphasizing the impact of ExuA’s upcoming launch. The company plans to leverage its Aytu RxConnect platform for efficient market penetration and is preparing for ExuA’s commercial launch by the end of 2025. Additionally, Aytu plans to invest approximately $10 million in launching ExuA in fiscal 2026, with expectations to ramp up commercial operations significantly in the subsequent quarters.</p>
<div class="lb-trans"><p>Aytu BioPharma 提供了 2025 财年的前瞻性指导，报告净收入为 6640 万美元，并强调 ExuA 即将推出的影响。公司计划利用其 Aytu RxConnect 平台实现高效的市场渗透，并准备在 2025 年底之前推出 ExuA。此外，Aytu 计划在 2026 财年投资约 1000 万美元用于 ExuA 的推出，并预计在随后的几个季度显著提升商业运营。</p>
</div><p>In summary, Aytu BioPharma’s earnings call conveyed a positive outlook, driven by the anticipated launch of ExuA and sustained financial performance. While challenges such as declining gross margins and potential competition in the ADHD market were acknowledged, the company’s strategic initiatives and financial achievements provide a solid foundation for future growth.</p>
<div class="lb-trans"><p>总之，Aytu BioPharma 的财报电话会议传达了积极的前景，受到 ExuA 预期推出和持续财务表现的推动。尽管承认了毛利率下降和 ADHD 市场潜在竞争等挑战，但公司的战略举措和财务成就为未来的增长提供了坚实的基础。</p>
</div>

Aytu BioPharma 乐观的财报电话会议重点介绍了 ExuA 的推出